All-trans retinoic acid (ATRA), the only clinically available cyto-differentiating agent, has potential for the therapy/chemoprevention of breast carcinoma. Given the heterogeneous nature of this tumor, a rational use of ATRA and derivatives (retinoids) in the clinic requires the identification of patients that would benefit from retinoidbased protocols. Here, we demonstrate that 23-32% of the human ERBB2 þ breast cancers show coamplification of retinoic acid receptor alpha (RARA), encoding the retinoic acid receptor, RARa. This represents a novel subtype of breast cancer characterized by remarkable sensitivity to ATRA and RARa agonists, regardless of positivity to the estrogen receptor, a known modulator of retinoid sensitivity. In estrogen-receptor-negative cellular models showing coamplification of ERBB2 and RARA, simultaneous targeting of the corresponding gene products with combinations of lapatinib and ATRA causes synergistic growth inhibition, cyto-differentiation and apoptosis. This provides proof-of-principle that coamplification of ERBB2 and RARA can be exploited for the stratified and targeted therapy of a novel subtype of breast cancer patients, with an approach characterized by tumor cell selectivity and low predicted toxicity. The available cellular models were exploited to define the molecular mechanisms underlying the antitumor activity of combinations between lapatinib and ATRA. Global gene expression and functional approaches provide evidence for three components of the antiproliferative/apoptotic responses triggered by lapatinib þ ATRA. Induction of the retinoiddependent RARRES3 protein by ATRA stabilizes the effect of lapatinib inhibiting ERBB2 phosphorylation. Upregulation and activation of the transcription factor FOXO3A integrates ATRA-dependent transcriptional and lapatinib-dependent posttranscriptional signals, controlling the levels of effector proteins like the antiapoptotic factor, BIRC5. Stimulation of the TGFb pathway by ATRA mediates other components of the apoptotic process set in motion by simultaneous targeting of ERBB2 and RARa.
Introduction
Breast carcinoma is classified according to the presence/ absence of estrogen receptor (ER), progesterone receptor and ERBB2 (also known as HER2/Neu) (Rubin and Yarden, 2001 ). ERBB2
þ patients used to have a poor prognosis until the advent of targeted therapy (Baselga, 2006; Baselga and Swain, 2009) , which relies on trastuzumab (Esteva et al.; Mariani et al., 2009 ) and lapatinib (Moreira and Kaklamani, 2010) . In spite of this progress, not all patients in this group benefit from trastuzumab-based therapies (Hudis, 2007; Esteva et al., 2010) . In addition, a subset of patients progress after an initial response. Innate and acquired resistance to HER2 targeting calls for the development of new and rational therapeutic approaches. This is likely to entail the development of combination strategies involving simultaneous targeting of determinants crucial for the growth and progression of the tumor (Abramson and Arteaga, 2011) .
All-trans retinoic acid (ATRA), the only clinically useful differentiating agent (Garattini et al., 2007) has potential for the therapy/chemoprevention of breast carcinoma (Decensi et al., 2000; Puntoni and Decensi, 2009) . Given the heterogeneous nature of this tumor, a rational use of ATRA and derivatives (retinoids) in the clinic requires the identification of patients that would benefit from retinoid-based protocols.
The antitumor activity of retinoids is mediated by specific nuclear receptors (RARa, b, g and RXRa, b, g, which are ligand-dependent transcription factors (Kastner et al., 1995; Chambon, 1996) . In breast cancer cells, RARa expression is controlled by estrogens, and high levels of the protein are observed in estrogen-receptorpositive (ER þ ) tumors (Sun et al., 1998) . RARa expression determines sensitivity of ER þ and refractoriness of ER À breast cancer cells to retinoids (Roman et al., 1993; Sheikh et al., 1993; Fitzgerald et al., 1997) .
Retinoic acid receptor alpha (RARA), the gene encoding RARa, maps close (0.65 Mb) to the ERBB2 locus, which is generally amplified in ERBB2 þ breast carcinoma. Here, we establish that a proportion of ERBB2 þ tumors are characterized by an amplicon encompassing RARA, which confers retinoid sensitivity upon the ER À neoplastic cell. This genetic makeup was exploited for concomitant targeting of ERBB2 and RARa, obtaining synergistic antitumor effects. The underlying molecular mechanisms were studied.
Results
A subgroup of breast carcinomas shows ERBB2/RARA coamplification We defined that a proportion of ERBB2 Table S1 ). Most cases (76%) proved positive for ERBB2 amplification by Q-PCR, when a conservative threshold value was applied. Coamplification of the RARA locus was found in 23% of the patients by Q-PCR and 32% by FISH. If samples were stratified for ER, no difference in the proportion of ERBB2 þ /RARA þ patients was evident.
ER À cell lines recapitulating ERBB2 and RARA coamplification are sensitive to retinoids Five ER À and five ER þ breast carcinoma cell lines overexpressing the ERBB2 protein and two negative controls (MDA-MB-231 and MCF-7) were evaluated for RARA amplification by Q-PCR (Figure 1c) . Except for ZR75.1, all ER À and ER þ cells with ERBB2 overexpression showed amplification of the corresponding gene. The ER þ line, UACC812, and the ER À lines, SKBR3 and AU565, showed ERBB2/RARA coamplification.
All ER þ cells contained more RARa than their ER À counterparts, and UACC812 synthesized the largest amounts of the receptor. In the context of ERnegativity, the two ERBB2 þ /RARA þ lines, SKBR3 and AU565, showed significant expression of RARa, whereas the ERBB2 þ /RARA À lines presented barely detectable levels of the protein (Figure 1c) .
We evaluated the sensitivity of cell lines to ATRA, determining their pIC 50 (-Log 10 of the concentration causing 50% maximal growth inhibition) (Figure 1c ; Supplementary Figure S1 Figure  S2a) . ATRA-dependent growth inhibition was accompanied by differentiation of SKBR3 but not MDA-MB-453 cells. This effect was detectable at 0.1 mM and maximal at 1 mM ATRA. Differentiation included accumulation of oil-red droplets (lactogenesis) (Supplementary Figure S2b ) and appearance of adherens junctions containing b-catenin, p120 and VE-cadherin (Supplementary Figure S2c ; Dusek and Attardi, 2011) . This was accompanied by the induction of the three proteins (see also Figure 2d ) and restructuring of the actin cytoskeleton. Growth inhibition and differentiation were directly correlated to ligand-dependent activation of retinoid receptors, as treatment with ATRA caused sustained activation of the transfected retinoid reporter, RARE-tk-Luc , only in SKBR3 cells (Supplementary Figure S2d) . To verify the role of RARA amplification, we compared the activities of ATRA (pan-RAR agonist) (Garattini et al., 2004) , the RARa agonist, AM580 (Gianni et al., 1996a) , and the RARg agonist, CD437 (Gianni et al., 1993) , in SKBR3 and MDA-MB-453 cells. AM580 and ATRA arrested the growth and induced differentiation of SKBR3 cells, whereas CD437 was inactive (Supplementary Figures S2a and e) . In SKBR3 cells, this is correlated with the activation of transfected RARE-tkLuc by the two agonists (Supplementary Figure S2f) . inhibited ERBB2 þ cell growth (Figure 2a ). Consistent with retinoid sensitivity and the relative levels of RARa, ATRA potentiated lapatinib activity only in ERBB2 þ / RARA þ cells (SKBR3 and AU565). In SKBR3 cells, the antiproliferative effect of lapatinib and ATRA was synergistic ( Figure 2b ) and lapatinib þ ATRA cooperation extended to lactogenic (Figure 2c ) and epithelial differentiation (Figure 2d ). In the ER þ context, ATRA enhanced growth inhibition by lapatinib in the retinoidsensitive ERBB2 þ cell lines, regardless of RARA amplification (see UACC812 as an example in Figure 2a) .
Lapatinib potentiates the activity of ATRA in ER
In SKBR3 cells, lapatinib þ ATRA induced cytotoxicity, which was not observed with lapatinib or ATRA alone (see sub-G1 fraction in Figure 3a) . This was the result of apoptosis, as indicated by PARP/caspase-3 cleavage (Figure 3b ). Apoptosis was confirmed by a specific assay (Paroni and Brancolini, 2011) based on overexpression of a mitochondria-targeted GFP protein containing caspase-dependent cleavage sites (DD-GFP) or inactive mutants, thereof (AA-GFP) serving as negative controls (Figure 3c ). RARA amplification was responsible for the cytotoxic/apoptotic response of SKBR3 cells, as cytotoxicity was replicated only by lapatinib þ AM580 (Figure 3d ). More importantly, RARa silencing reduced the DD-GFP cleavage observed with lapatinib þ ATRA (Figure 3e ).
ATRA and lapatinib cross talk perturbs the SKBR3 cell transcriptome
We determined the transcriptomes of SKBR3 cells treated for 12 and 48 h with lapatinib, ATRA or the combination. A set of 2,846 genes (active dataset) was modified by one of the factors (lapatinib, ATRA or interaction; two-way ANOVA, Po10 À5 ) in at least one of the time points considered (Supplementary Table S2 ). Principal component analysis indicated that the transcriptional effect of lapatinib was short-lived, with Figure S3a) . ATRA exerted a prolonged action regardless of lapatinib addition. ANOVA was followed by time-course analysis considering all the possible contrasts (Baesian Estimation of Temporal Regulation) (Aryee et al., 2009) . We focused on the subgroup of genes modulated by lapatinib þ ATRA relative to lapatinib or ATRA alone, extracting four clusters according to the expression profile (Supplementary Figure S3b) . Cluster 1, comprising genes regulated by lapatinib but not by ATRA, was enriched in genes controlling cell cycle and DNA replication (Supplementary Figure S3c) . The overall effect of lapatinib was repressive, causing downregulation of 75% of the modulated genes. In the presence of lapatinib alone, most genes modified at 12 h returned to baseline or showed opposite regulation at 48 h, whereas induction or repression was maintained with lapatinib þ ATRA. This was consistent with principal component analysis and indicated that ATRA stabilized the transcriptional effects of lapatinib. Cluster 2 contained genes regulated by ATRA but not by lapatinib (Supplementary Figure S3d) . The combination exerted a potentiating effect on ATRA-dependent expression of many genes. The type of genes enriched in this cluster was heterogeneous, although controllers of development and cell growth stood out. Cluster 3 consisted of genes modulated by lapatinib and ATRA concomitantly (Supplementary Figure S3e) . The majority was upregulated by ATRA and cotreatment with lapatinib resulted in additive/synergistic effects. Among the enriched genes, those involved in lipid metabolism and apoptosis were relevant. Cluster 4 gathered genes activated or repressed only by lapatinib þ ATRA, and was enriched for determinants of cell cycle and apoptosis (Supplementary Figure S3f ).
Inhibition of ERBB2 by lapatinib enhances the transcriptional responses to ATRA
We studied the molecular mechanisms underlying the action of lapatinib on the retinoid-dependent arm of the cross talk. In SKBR3 cells, ATRA reduced the amounts of the RARa protein (Supplementary Figure S4a) , without affecting the corresponding transcripts (Supplementary Figure S4b ). This was consistent with activation and subsequent proteasome-dependent degradation of the receptor . Lapatinib too downregulated the RARa protein, resulting in additive effects upon cotreatment with the retinoid. These effects suggested increased activation of RARa by lapatinib. In the same conditions, modulation of RARg by lapatinib and/or ATRA was not observed. Consistent with this idea, the expression profiles of retinoid target genes Blomhoff, 2002, 2005) , many of which were indeed regulated by ATRA in SKBR3 cells (Po10 À5 , ANOVA), showed potentiated expression upon addition of lapatinib (Supplementary Figure S4c) . However, direct stimulation of RARa by lapatinib was unlikely to explain the observed effects. In fact, although ATRA and the specific RARa agonist, AM580, activated the retinoid-dependent RARE-tk-Luc reporter in SKBR3 cells, activation was not further enhanced by the addition of lapatinib (Supplementary Figure S4d) . Similar results were obtained in MDA-MB-453 cells overexpressing RARa and RARE-tk-Luc.
Control of ERBB2 phosphorylation by RARRES3 is a component of the cross talk between lapatinib and ATRA Temporal regulation of cell cycle genes suggested that ATRA prolonged the antiproliferative effect of lapatinib and this was confirmed experimentally (Figure 4a) . In SKBR3 cells, lapatinib induced a transient increase (24-48 hours) of the G1-fraction at the expenses of the Sfraction, whereas ATRA exerted a late G1-arrest. The combination enhanced and stabilized the lapatinibdependent G1-block.
Short-term treatment (1 h) with lapatinib suppressed phosphorylation/activation of ERBB2, resulting in hypo-phosphorylation of the downstream kinases, AKT and ERK2 (Figure 4b, left) . These effects were not altered by ATRA. Inhibition of ERBB2, AKT and ERK2 phosphorylation by lapatinib was short-lived reverting to baseline by 48 h (Figure 4b, right) . In contrast, ATRA caused a late inhibitory effect on ERBB2 and downstream kinases from 24 h onwards.
In the presence of lapatinib, this resulted in long-lasting suppression of ERBB2 phosphorylation.
Among the retinoid targets in the active dataset, retinoic acid receptor responder 3 (RARRES3) (Huang et al., 2000; Sturniolo et al., 2003; Shyu et al., 2005; Tsai et al., 2007 Tsai et al., , 2009 Barral et al., 2009) was one of the genes with the highest induction ratio (combination vs control at 48 h). The effect of the combination was significantly different from single drug treatment (Figure 4c , Supplementary Table S2 ). Considering that RARRES controls the levels of ERBB2 in ovarian cancer (Ou et al., 2008) , the corresponding gene was silenced to evaluate its significance for the long-term regulation of ERBB2 by ATRA in SKBR3 cells. Silencing of RARRES3 reduced the delayed ATRAdependent inhibition of ERBB2 phosphorylation (Figure 4d ). This effect was not the consequence of a change in the amounts of the protein.
TGFb, FOXO3A and SMAD3 are central to the synergism between lapatinib and ATRA To further identify molecular determinants of the cross talk between lapatinib and ATRA, we performed focused network analysis on the active dataset. We linked prominent breast carcinoma growth factors to transcription factors, and downstream gene products involved in cell cycle and apoptosis. The network was subsequently integrated with the RARa, ERBB2, ERK2 and AKT nodes (Supplementary Figure S5) .
TGFb2 is a growth factor and mediates the action of ATRA in various cell types (Zujewski et al., 2001; Dokmanovic et al., 2002; Danforth, 2004; Mucida and Cheroutre, 2007; Wang et al., 2007; Xiao et al., 2008) . In SKBR3 cells, TGFb2 and the antimetastatic receptor, TGFBRII (Yang et al., 2008b; Tan et al., 2009) , were upregulated by ATRA and were further induced by lapatinib þ ATRA (Supplementary Figure S5) . This implied that some of the pathways activated by lapatinib and/or ATRA involved TGFb mediation. SMAD family member 3 (SMAD3) and forkhead box O3 (FOXO3A) were among the top 10 transcription factors regulated by ATRA and/or lapatinib (Supplementary Figure S5 and Supplementary Table S2), for which there was significant overconnection in the active dataset (Supplementary Table S3 ). The two groups of FOXO3A and SMAD3 target genes were characterized by the presence of five common elements involved in cell growth and apoptosis (CDKN2B, CDKN2D, FOXM1, BCL2L11 and BIRC5/survivin) (Supplementary Figures S6a and b) . The expression profile of these genes was consistent with a role in integrating Antitumor activity of retinoids and lapatinib G Paroni et al growth inhibitory and apoptotic signals originating from SMAD3 and FOXO3A. In SKBR3 cells, SMAD3 or FOXO3A mRNAs and proteins were upregulated predominantly by ATRA, although further upregulation was afforded by lapatinib þ ATRA, confirming and extending the microarray results (Figures 5a and b) . Induction of SMAD3 and FOXO3A was also observed in the other ER
À counterparts, MDA-MB453 and HCC1569 (Supplementary Figure S6c) , strengthening their relevance for the cross talk between lapatinib and ATRA. FOXO3A and SMAD3 proteins were induced by AM580, whereas neither CD437 nor the RARb agonist, BMS641, exerted any significant effect (Supplementary Figure S6d ). Additionally, silencing of RARa blunted the induction of both SMAD3 and FOXO3A (Supplementary Figure S6e) . Thus, ATRA-regulated induction of SMAD3 and FOXO3A was dependent on RARa activation. SMAD3 activation is TGFb-dependent, whereas activation of FOXO3A integrates transcriptional and posttranscriptional signals We evaluated whether lapatinib þ ATRA affected the biological activity of SMAD3 and FOXO3A (Figure 5c Antitumor activity of retinoids and lapatinib G Paroni et al SMAD3 (Figure 5c ). In contrast, SB431542 blunted the phosphorylation/activation of SMAD3 observed with ATRA and lapatinib þ ATRA. Thus, ATRA was necessary and sufficient to cause both activation and induction of the SMAD3 protein, but only activation required TGFb.
FOXO3A activation was assessed by measuring its subcellular localization (Afonja et al., 2004) . Lapatinib caused complete relocalization of FOXO3A into the nucleus (Figure 5d ) without affecting FOXO3A protein expression levels (Figure 5b ). In contrast, ATRA did not alter the intracellular compartmentalization of FOXO3A (Figure 5d ), although it induced the protein significantly (Figure 5b ). Lapatinib-dependent FOX-O3A sequestration into the nucleus was a rapid process completed within 1 h (Supplementary Figures S7a and  b) . Thus, the result of lapatinib þ ATRA treatment was the sum of the two effects exerted separately by ATRA and lapatinib, that is, accumulation of large amounts of FOXO3A and retention into the nucleus. The action of lapatinib likely involved inhibition of AKT-dependent FOXO3A phosphorylation, with consequent sequestration into the nucleus and protection from proteasome-dependent degradation (Yang and Hung, 2009 ). In conclusion, FOXO3A represents a central effector of the cross talk, integrating transcriptional induction by ATRA with posttranslational activation by lapatinib.
TGF, RARRES and FOXO3A contribute to the apoptotic response activated by lapatinib þ ATRA We evaluated the role of TGFb, FOXO3A and RARRES3 in the apoptotic response triggered by lapatinib þ ATRA.
The TGF-receptor inhibitor, SB431542, protected SKBR3 cells from the apoptotic response triggered by lapatinib þ ATRA, as assessed by the DD-GFP cleavage assay (Figure 6a, left) . Protection was likely to be the consequence of a predominant action on the retinoid arm of the cross talk, as suggested by the effects of SB431542 on the antiproliferative action of lapatinib, ATRA and the combination (Figure 6a, right) . SB431542 did not alter lapatinib-dependent growth inhibition, whereas it reduced the antiproliferative effect of ATRA. This resulted in partial reversion of the cumulative action of lapatinib þ ATRA.
Silencing experiments demonstrated that FOXO3A contributed to the apoptotic process activated by combined targeting of ERBB2 and RARa in SKBR3 cells (Figure 6b) . Part of this effect involved regulation of effector proteins like BIRC5. BIRC5 is a FOXO3A target gene coding for an antiapoptotic factor (Yang et al., 2008a; Guha et al., 2009) . Downregulation of BIRC5 mRNA Figure S5) and protein (Figure 6c ) by lapatinib and ATRA was enhanced and prolonged by the combination. Silencing of FOXO3A attenuated downregulation of BIRC5 by lapatinib and/or ATRA (Figure 6d) . In a similar fashion, silencing of RARRES3 was accompanied by protracted inhibition of the DD-GFP cleavage observed with lapatinib þ ATRA (Figure 6e ). This indicated that long-term inhibition of ERBB2 by ATRA via RARRES3 induction is likely to represent a crucial determinant in the apoptotic process activated by combinations of lapatinib and ATRA.
Discussion
Retinoids have been proposed in the adjuvant treatment of breast carcinoma for their ability to inhibit growth and induce morphological or phenotypic differentiation of breast carcinoma cell lines (Yang et al., 2002; Paik et al., 2003) . An effective clinical use of retinoids in breast carcinoma requires the identification of sensitive patient subpopulations, as this tumor is highly heterogeneous. The goal can be achieved in a rational way by definition of the molecular determinants controlling the sensitivity of the neoplastic cell to ATRA and derivatives. Preclinical and clinical data indicate that the levels of RARa may represent one such determinant, as retinoid-responsive ERa þ breast carcinoma cells contain much higher levels of the receptor than retinoidrefractory ERa À cells (Roman et al., 1993; Sheikh et al., 1993; Fitzgerald et al., 1997) .
In this report, we establish that a significant fraction of all ERBB2 breast carcinomas is characterized by coamplification of the RARA locus. Amplification of RARA leads to increased expression of an active form of the corresponding RARa protein, and is associated with sensitivity to the antiproliferative/cyto-differentiating action of ATRA. This is of particular relevance in the context of ERa À tumors, which are refractory to retinoids. In ER À
/ERBB2
þ /RARA þ cells, sensitivity to the retinoid is further enhanced by the tyrosine kinase inhibitor, lapatinib, which targets ERBB2 and EGFR1 (epidermal growth factor receptor 1). In our experimental conditions, the enhancing effect of lapatinib is likely to be the result of a specific action on ERBB2, as synergistic inhibition of SKBR3 cell growth was recently reported also for combinations of the specific ERBB2 inhibitor, trastuzumab and ATRA (Koay et al, 2010) . Our work represents proof-of-concept that simultaneous targeting of ERBB2 and RARa has the potential to be exploited in the treatment of a subpopulation of breast carcinoma patients characterized by coamplification of the corresponding two genes. In principle, combinations between ATRA or RARa agonists and lapatinib are promising for at least two reasons. First, combined targeting of ERBB2 and RARa results in highly synergistic interactions. Second, treatment with the combination is likely to target the cancer cell selectively. These two actions are foreseen to increase the therapeutic index of the retinoid. Current experimental work aims at strengthening the rationale of our therapeutic approach in vivo. However, this will require the generation of novel preclinical models recapitulating the coamplification of ERBB2 and RARA, as the cell lines currently available do not give rise to tumor xenografts in immune-deficient animals.
In ERBB2 þ /RARA þ cells, the cross talk between lapatinib and ATRA is two-way. The action exerted by ATRA on the ERBB2 arm of the cross talk involves sustained and prolonged inhibition of ERBB2 phosphorylation/activation by induction of RARRES3. Lapatinib affects the retinoid-dependent arm of the cross talk in a more complex manner and direct modulation of RARa transcriptional activity by lapatinib by the inhibition of ERBB2-regulated AKT is unlikely (Srinivas et al., 2006) .
We identified not only RARRES3 but also TGFb and FOXO3A as crucial players in the cross talk. TGFb is predominantly involved in mediating some of the cellular responses activated by ATRA. Interestingly, retinoid-dependent induction and activation of the signal transducer, SMAD3, is not necessary for the apoptotic component of TGFb activity in our cellular system, as silencing of the gene did not alter DD-GFP cleavage triggered by lapatinib þ ATRA (data not shown). As for FOXO3A, full activation of the transcription factor involves direct induction by ATRA and sequestration into the nucleus by lapatinib. In our model (Supplementary Figure S8) , these combined effects result in the regulation of various effector molecules potentially relevant for the growth inhibitory and apoptotic effects of the combination between lapatinib and ATRA. On the basis of our results, we propose that BIRC5 downregulation is an effector of FOXO3A-dependent apoptosis of SKBR3 cells.
RARRES3, TGFb and FOXO3A define three pathways contributing to the apoptotic program triggered by lapatinib þ ATRA in ER
The level of integration among these pathways is incompletely understood, although experiments, which were not the object of this work demonstrated that RARRES3 silencing did not alter FOXO3A mRNAs expression/ regulation. Conversely, silencing of FOXO3A had no effect on RARRES3 mRNA expression, in line with direct transcriptional activation of the RARRES3 gene by ATRA and lapatinib þ ATRA.
In conclusion, our work provides the initial rationale for the design of clinical studies aimed at evaluating the feasibility of our approach based on simultaneous targeting of ERBB2 and RARa for the stratified therapy of ER
À

/ERBB2
þ /RARA þ breast cancer patients. It also provides new insights into the biology of this subtype of tumor, defining new molecular determinants and intracellular pathways involved in the proliferation/ survival of the neoplastic cell.
Materials and methods
ERBB2 and RARA copy number assessment by FISH and Q-PCR analyses FISH assays of ERBB2 were performed on 4-mm paraffin sections using the PathVysion kit (Abbott Laboratories, Abbott Park, IL, USA). The ERBB2 probe was labeled with SpectrumOrange, and the CEP17 control probe (D17Z1, 17p11.1-q11.1) with SpectrumGreen. In the case of FISH assays on RARA, paraffin sections were hybridized with the Smith-Magenis assay probe set, which includes a 17p11.2 DNA probe labeled with SpectrumOrange, encompassing the SHMT1, TOP3, FLII and LLGL1 loci, and a 17q21.2 DNA probe labeled with SpectrumGreen, encompassing the GRB7, MLN51, SHGC-146999, THRA and RARA loci (Abbott Laboratories).
DNA from cell lines was prepared with the DNeasy Blood & Tissue Kit (Qiagen, Valencia, CA, USA). DNA from paraffinembedded patient samples was obtained using the QuickExtract FFPE DNA Extraction Kit (Epicentre Biotechnologies, Madison, WI, USA). ERBB2 and RARA copy number was quantified by real-time quantitative PCR (Q-PCR), using the 7300 (SDS software v 1.3) System (Applied Biosystems, Foster City, CA, USA). Predesigned TaqMan Copy Number Assays Hs01079964_cn (RARA) and Hs05520410_cn (ERBB2) were from Applied Biosystems. The ribonuclease P RNA component H1 gene (RPPH1), located on chromosome 17q11.2 was used as reference control. Samples were analyzed in triplicate. Human genomic DNA (Cat.G1471) (Promega, Madison, WI, USA) was run in every assay as a calibrator sample. Further details are available in Supplementary Methods.
Cell cultures, chemicals and fluorescence-activated cell sorting analysis BT474 and ZR75.1 were a kind gift from Dr Elda Tagliabue (Istituto Nazionale dei Tumori, Milano, Italy), while EFM-192A cells were purchased from DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany). All the other cell lines were obtained from the ATCC (American Type Culture Collection, Manassas, VA, USA). Except for HCC1569 (basal A) and MDA-MB231 (Basal B), all the cell lines are characterized by a luminal phenotype (35). SKBR3 cells stably transfected with the DD-GFP plasmid were selected and maintained in 250 mg/ml G418 (Invitrogen, Carlsbad, CA, USA). Cell cultures were grown in phenol redfree Dulbecco's modified Eagle's medium supplemented with 5% fetal calf serum, glutamine (2 mM) at 37 1C in 5% CO 2 atmosphere. ATRA was from Sigma (ST Louis, MI, USA) and lapatinib from LC Laboratories (Woburn, MA, USA). Viability was measured by the trypan blue exclusion and the sulforhodamine B assays. The RAR specific agonists, CD437 and AM580, were previously described (Gianni et al., 1996b) , and the TGF-receptor kinase inhibitor, SB-431542, was from Sigma. Combination effects of lapatinib and ATRA were measured with the isobologram method (Colombo et al., 2011) . Flowcytometric (fluorescence-activated cell sorting) analysis of DNA content was performed as described (Lupi et al., 2004) .
Western blots
Western blots were performed as detailed (Terao et al, 2011) with the antibodies described in Supplementary methods. Blots were developed and analyzed using an automated fluorescence scanner (Typhoon, GE Healthcare, Fairfield, CT, USA).
Immunofluorescence, time-lapse analysis and oil red O assay For indirect immunofluorescence microscopy, cells were fixed with 3% paraformaldehyde and permeabilized with 0.1% Triton X 100 in phosphate-buffered saline for 5 min. Fixed cells were incubated for 45 min with the anti-VE-cadherin, anti-p120, anti-b-catenin, and anti-FOXO3A antibodies. Positive cells were identified following further incubation for 30 min with 488 or 543 Alexa-conjugated secondary antibodies (Invitrogen). Time-lapse analysis of FOXO3A-GFP or DD-GFP transfected SKBR3 cells was performed using the Imaging Station cell^R (Olympus, Center Valley, PA, USA). The FOXO3A-GFP plasmid was kindly provided by MienChie Hung (The University of Texas). Oil red O assays were performed as described by Mueller et al. (1998) .
